FLYSYN is under clinical development by VERAXA Biotech and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FLYSYN’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FLYSYN is under development for the treatment of acute myeloid leukemia (AML). It is administered intravenously as an infusion. It is a monoclonal antibody. The drug candidate targets Fms-related tyrosine kinase 3 ligand that is expressed on tumor cells.
VERAXA Biotech overview
VERAXA Biotech (Veraxa) develops functional antibodies and antibody-drug conjugates (ADC’s) for the biopharmaceutical industry. The company is headquartered in Zurich, Switzerland.
For a complete picture of FLYSYN’s drug-specific PTSR and LoA scores, buy the report here.